Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following three subcutaneous injections of CAD106 https://kusajili.com:443/Trial/ZqXNMPDqiEuIo46E_5BuIg%24a-52-week-multi-center-randomized-double-blind-placebo-controlled-time-lagged-parallel-group-study-in-patients-with-mild-to-mod
I have read and accept the terms of use of the site and the Privacy Policy
Send your message